176 related articles for article (PubMed ID: 19803536)
1. Economic evaluation and cost-effectiveness thresholds: signals to firms and implications for R & D investment and innovation.
Vernon JA; Goldberg R; Golec J
Pharmacoeconomics; 2009; 27(10):797-806. PubMed ID: 19803536
[TBL] [Abstract][Full Text] [Related]
2. Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment.
Fugel HJ; Nuijten M; Postma M
N Biotechnol; 2016 Dec; 33(6):860-867. PubMed ID: 27664792
[TBL] [Abstract][Full Text] [Related]
3. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
Pekarsky B
Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
[TBL] [Abstract][Full Text] [Related]
4. One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry.
Billette de Villemeur E; Versaevel B
J Health Econ; 2019 May; 65():260-283. PubMed ID: 31158785
[TBL] [Abstract][Full Text] [Related]
5. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
Han E; Kim TH; Jeung MJ; Lee EK
Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
[TBL] [Abstract][Full Text] [Related]
6. Role of pharmacoeconomic analysis in R&D decision making: when, where, how?
Miller P
Pharmacoeconomics; 2005; 23(1):1-12. PubMed ID: 15693724
[TBL] [Abstract][Full Text] [Related]
7. Investment decisions in pharmaceutical R&D projects.
Pandey M
Drug Discov Today; 2003 Nov; 8(21):968-71. PubMed ID: 14643156
[No Abstract] [Full Text] [Related]
8. Ex post value reimbursement for pharmaceuticals.
Gravelle HS
Med Decis Making; 1998; 18(2 Suppl):S27-38. PubMed ID: 9566465
[TBL] [Abstract][Full Text] [Related]
9. The Interaction between Price Negotiations and Heterogeneity: Implications for Economic Evaluations.
O'Donnell H; McCullagh L; Barry M; Walsh C
Med Decis Making; 2020 Feb; 40(2):144-155. PubMed ID: 32009545
[TBL] [Abstract][Full Text] [Related]
10. The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.
Cockburn I; Long G
Expert Opin Ther Pat; 2015 Jul; 25(7):739-42. PubMed ID: 25927945
[TBL] [Abstract][Full Text] [Related]
11. Impact of product subsidies on R&D investment for new energy vehicle firms: Considering quality preference of the early adopter group.
Meng W; Wang Y; Li Y; Huang B
PLoS One; 2020; 15(7):e0236626. PubMed ID: 32735570
[TBL] [Abstract][Full Text] [Related]
12. Examining the link between price regulation and pharmaceutical R&D investment.
Vernon JA
Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
[TBL] [Abstract][Full Text] [Related]
13. The use of health economic information by reimbursement authorities.
Drummond MF
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919
[TBL] [Abstract][Full Text] [Related]
14. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
Franken M; Koopmanschap M; Steenhoek A
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
[TBL] [Abstract][Full Text] [Related]
15. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development.
Bodrogi J; Kaló Z
Br J Pharmacol; 2010 Apr; 159(7):1367-73. PubMed ID: 20132213
[TBL] [Abstract][Full Text] [Related]
16. The opportunity cost of capital: development of new pharmaceuticals.
Chit A; Chit A; Papadimitropoulos M; Krahn M; Parker J; Grootendorst P
Inquiry; 2015; 52():. PubMed ID: 25933615
[TBL] [Abstract][Full Text] [Related]
17. The changing structure of the pharmaceutical industry.
Cockburn IM
Health Aff (Millwood); 2004; 23(1):10-22. PubMed ID: 15002624
[TBL] [Abstract][Full Text] [Related]
18. The effect of pharmacoeconomics on company research and development decisions.
Grabowski H
Pharmacoeconomics; 1997 May; 11(5):389-97. PubMed ID: 10168028
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacoeconomics--survey and status].
Pedersen KM
Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
[TBL] [Abstract][Full Text] [Related]
20. The Arthroplasty Candidacy Help Engine tool to select candidates for hip and knee replacement surgery: development and economic modelling.
Price A; Smith J; Dakin H; Kang S; Eibich P; Cook J; Gray A; Harris K; Middleton R; Gibbons E; Benedetto E; Smith S; Dawson J; Fitzpatrick R; Sayers A; Miller L; Marques E; Gooberman-Hill R; Blom A; Judge A; Arden N; Murray D; Glyn-Jones S; Barker K; Carr A; Beard D
Health Technol Assess; 2019 Jun; 23(32):1-216. PubMed ID: 31287051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
